SAN DIEGO, Feb. 17, 2015 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) today announced that the
manuscript "Tumor-Associated Hyaluronan Limits Efficacy of
Monoclonal Antibody Therapy" has been published in Molecular
Cancer Therapeutics (February
2015 14:523-532). The paper expands on previously reported
data in a poster presentation at the American Society of Clinical
Oncology 2015 Gastrointestinal Cancers Symposium in San Francisco, CA. The manuscript was written
and funded by Halozyme Therapeutics, Inc.
"This paper provides a comprehensive description of the
preclinical characterization of how investigational PEGPH20 has the
potential to enhance the anti-cancer activity of the accompanying
immunotherapy (trastuzumab and immune cells) in a high hyaluronan
(HA) tumor model," stated H. Michael
Shepard, Ph.D., Vice President and Chief Scientific Officer.
"These data suggest that PEGPH20 not only has the potential to
enhance the access of drug into an HA-high tumor by reducing the
pressure inside of the tumor, but also breaks the physical barrier
on the cancer cell surface, thus potentially exposing the cancer
cells and allowing the immune system to attack the malignant cells
more efficiently."
Publication Summary:
- PEGPH20 enhances HA-high breast cancer cell killing by
trastuzumab and natural killer (NK) cells in vitro.
- Upon PEGPH20 application, synapse formation between immune and
cancer cells occurs and promotes the killing capacity of NK
cells.
- PEGPH20, by removing HA from the cancer cell surface,
potentially allows greater contact of NK cells to tumor cells, a
key process involved in antibody-dependent cell-mediated
cytotoxicity of cancer cells.
About PEGPH20
PEGPH20 is an investigational PEGylated form of Halozyme's
proprietary recombinant human hyaluronidase under clinical
development for the systemic treatment of tumors that accumulate
hyaluronan.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on
developing and commercializing novel oncology therapies that target
the tumor microenvironment. Halozyme's lead proprietary program,
our investigational drug PEGPH20, applies a unique approach to
targeting solid tumors, allowing increased access of
co-administered cancer drug therapies to the tumor. PEGPH20
is currently in development for metastatic pancreatic cancer and
non-small cell lung cancer and has potential across additional
cancers in combination with different types of cancer therapies. In
addition to its proprietary product portfolio, Halozyme has
established value-driving partnerships with leading pharmaceutical
companies including Roche, Pfizer, Janssen and Baxter for its drug delivery platform,
ENHANZE™, which enables biologics and small molecule compounds that
are currently administered intravenously to be delivered
subcutaneously. Halozyme is headquartered in San Diego, CA. For more information on how we
are innovating, please visit our corporate website at
www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth
above include forward-looking statements (including, without
limitation, statements concerning future actions relating to the
development of PEGPH20) that involve risk and uncertainties that
could cause actual results to differ materially from those in the
forward-looking statements. The forward-looking statements are
typically, but not always, identified through use of the words
"believe," "enable," "may," "will," "could," "intends," "estimate,"
"anticipate," "plan," "predict," "probable," "potential,"
"possible," "should," "continue," and other words of similar
meaning. Actual results could differ materially from the
expectations contained in forward-looking statements as a result of
several factors, including unexpected developments in clinical
trials (including potential additional safety events), unexpected
expenditures and costs, unexpected results or delays in development
and regulatory review, regulatory approval requirements, unexpected
adverse events and competitive conditions. These and other factors
that may result in differences are discussed in greater detail in
Halozyme's Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission on November 10,
2014.
Investor Contact:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com
Media Contact:
Susan Neath Francis
212-301-7182
sfrancis@w2ogroup.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-announces-preclinical-study-results-of-pegph20-published-in-molecular-cancer-therapeutics-300036609.html
SOURCE Halozyme Therapeutics, Inc.